Search

Your search keyword '"Deri, Norma"' showing total 224 results

Search Constraints

Start Over You searched for: Author "Deri, Norma" Remove constraint Author: "Deri, Norma"
224 results on '"Deri, Norma"'

Search Results

1. Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings

2. Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina

3. Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina

4. Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study

5. Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry

6. Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina

7. Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina

8. Guía de práctica clínica: tratamiento agudo de las enfermedades inflamatorio-desmielinizantes del sistema nervioso central: esclerosis múltiple, espectro de la neuromielitis óptica, encefalomielitis diseminada aguda, enfermedades asociadas a anticuerpos antiglicoproteína de la membrana del oligodendrocito, mielitis aguda y neuritis óptica. Elaborada por el Grupo de Trabajo de Enfermedades Desmielinizantes. Sociedad Neurológica Argentina

9. Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

10. Guía de práctica clínica: tratamiento sintomático de esclerosis múltiple. Grupo de Trabajo de Enfermedades Desmielinizantes. Sociedad Neurológica Argentina

11. Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina

12. Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina

13. Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?

14. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

15. Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

16. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM

17. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)

18. Usage trend of oral drugs for multiple sclerosis patients in Argentina

20. Guías de práctica para indicación y contraindicaciones de vacunación de pacientes con esclerosis múltiple

21. Do immunosuppressive treatments influence immune responses against adenovirusbased COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.

22. Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.

23. Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina

24. Consensus recommendations on the management of multiple sclerosis patients in Argentina

26. Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)

27. The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions

28. Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry

29. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

30. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

31. Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)

32. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

33. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

34. Bases racionales de prescripción para médicos neurólogos

35. Comparative effectiveness in multiple sclerosis: A methodological comparison

36. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

37. Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

38. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis

39. sj-docx-2-mso-10.1177_20552173231154712 - Supplemental material for Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

40. sj-docx-3-mso-10.1177_20552173231154712 - Supplemental material for Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

41. sj-docx-1-mso-10.1177_20552173231154712 - Supplemental material for Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

42. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

43. Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM

44. Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.

45. Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina

46. Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study

48. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

49. SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS IN ARGENTINA.

50. Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)

Catalog

Books, media, physical & digital resources